Candriam Luxembourg S.C.A. lessened its position in CryoLife, Inc. (NYSE:CRY) by 25.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,000 shares of the medical equipment provider’s stock after selling 15,000 shares during the quarter. Candriam Luxembourg S.C.A. owned about 0.13% of CryoLife worth $1,022,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Principal Financial Group Inc. lifted its position in shares of CryoLife by 21.0% in the third quarter. Principal Financial Group Inc. now owns 258,323 shares of the medical equipment provider’s stock valued at $5,864,000 after acquiring an additional 44,777 shares in the last quarter. Prudential Financial Inc. lifted its position in CryoLife by 51.6% during the third quarter. Prudential Financial Inc. now owns 133,863 shares of the medical equipment provider’s stock worth $3,039,000 after buying an additional 45,580 shares in the last quarter. Monarch Partners Asset Management LLC purchased a new position in CryoLife during the third quarter worth approximately $413,000. Crossmark Global Holdings Inc. purchased a new position in CryoLife during the third quarter worth approximately $259,000. Finally, Thomson Horstmann & Bryant Inc. lifted its position in CryoLife by 139.0% during the third quarter. Thomson Horstmann & Bryant Inc. now owns 224,518 shares of the medical equipment provider’s stock worth $5,096,000 after buying an additional 130,593 shares in the last quarter. Institutional investors and hedge funds own 70.34% of the company’s stock.

CRY has been the topic of a number of analyst reports. BidaskClub downgraded CryoLife from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Zacks Investment Research downgraded CryoLife from a “buy” rating to a “sell” rating in a research report on Wednesday, August 2nd. Canaccord Genuity reiterated a “buy” rating and set a $25.00 price objective on shares of CryoLife in a research report on Monday, October 9th. Lake Street Capital raised their target price on CryoLife to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Finally, TheStreet cut CryoLife from a “b” rating to a “c+” rating in a research note on Monday, October 30th. Two investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $23.63.

In other news, VP David C. Gale sold 20,000 shares of the business’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $19.63, for a total value of $392,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Amy Horton sold 4,000 shares of the business’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $19.00, for a total value of $76,000.00. Following the completion of the sale, the chief accounting officer now directly owns 98,705 shares of the company’s stock, valued at $1,875,395. The disclosure for this sale can be found here. Insiders have sold a total of 229,240 shares of company stock valued at $4,888,065 over the last ninety days. 6.00% of the stock is owned by company insiders.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/candriam-luxembourg-s-c-a-decreases-stake-in-cryolife-inc-cry/1713856.html.

CryoLife, Inc. (CRY) opened at $19.20 on Friday. CryoLife, Inc. has a one year low of $14.02 and a one year high of $24.00. The company has a market capitalization of $642.39, a price-to-earnings ratio of 46.83 and a beta of 0.82. The company has a current ratio of 5.96, a quick ratio of 4.90 and a debt-to-equity ratio of 0.29.

CryoLife (NYSE:CRY) last released its earnings results on Monday, October 30th. The medical equipment provider reported $0.08 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.08. CryoLife had a return on equity of 6.43% and a net margin of 5.28%. The firm had revenue of $44.00 million during the quarter, compared to analysts’ expectations of $44.60 million. During the same period in the previous year, the firm posted $0.13 EPS. CryoLife’s revenue for the quarter was down 2.9% on a year-over-year basis. analysts anticipate that CryoLife, Inc. will post 0.28 earnings per share for the current fiscal year.

About CryoLife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Institutional Ownership by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.